This page was printed from the Northern & Eastern Devon Formulary and Referral site at
Please ensure you are using the current version of this document
For the latest updates and advice on coronavirus (COVID-19), please visit the NHS website.
For a summary of Formulary updates specific to the COVID-19 pandemic, please click here.
For Clinical Referral Guideline (CRG) updates specific to the COVID-19 pandemic, please click here. The NHS Devon CCG Medicines Optimisation Team have produced a COVID-19 Information and Guidance page, which features a frequently asked questions section, please click here.
In February 2021, the North & East Devon and South & West Devon Formulary Interface Groups (FIGs) merged to form a single Devon-wide FIG. The resulting multi-stakeholder group includes representatives from NHS Devon CCG and primary and secondary care providers.
Informative tables have been added to the guidance which give the indicative carbon footprint (as CO2eq) per puff of each inhaler as well as estimates of annual CO2eq and equivalent car miles for the recommended regimens.
Formulary guidance has been reviewed and updated. The guidance provides recommendations on advice to reduce the spread of impetigo, initial treatment, reassessment and further treatment, referral and seeking specialist advice, and appropriate choice of antimicrobial. Please see the formulary for further information.
Formulary guidance for recurrent UTI and catheter-associated UTI has been revised and updated. Please see the formulary for further guidance.
Formulary guidance has been reviewed and updated. Please see the formulary for further guidance.
The following Specialised Medicines Service (SMS) prescribing guidelines have been partially updated to provide clarity in respect of prescribing and monitoring responsibilities at initiation of treatment (specialists will prescribe and monitor during the first 28 days, GPs to continue prescribing and monitoring thereafter):
* Please note, these changes were agreed at the March 2020 meeting of the N&E Devon FIG, the delay in publication was due to resources being diverted to support the NHS response to the COVID-19 pandemic.
The following Specialised Medicines Service (SMS) prescribing guidelines have been partially updated to include advice from the recent MHRA Drug Safety Update “Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly doses” (September 2020). The new recommendations strengthen existing advice highlighting the once weekly dosing of methotrexate for autoimmune disease but are unlikely to represent a significant change in practice.